Retatrutide and Joint Pain: Evidence, Risks, and UK Guidance Retatrutide and joint pain is an emerging area of interest as this investigational triple receptor agonist progresses through clinical trials
Effects of typical inducers on olfactory xenobiotic-metabolizing enzyme, transporter, and transcription factor expression in rats
Lilly submitted the diabetes NDA in October 2021, the FDA approved Mounjaro in May 2022, and the obesity approval (Zepbound) followed in November 2023
A population pharmacokinetic model developed using data from clinical trials of subcutaneous and intravenous semaglutide was modified to include data from six trials of oral semaglutide in healthy volunteers or patients with T2D and renal or hepatic impairment [66, 67]
all subjects had an additional health condition related to obesity, and nearly 20% of them had type 2 diabetes
Dont combine it with a prescribed GLP-1, and dont keep using it